STOCK TITAN
  1. Home
  2. Sec-filings
  3. BIOA
  4. [Form 4] BioAge Labs, Inc. Insider Trading Activity

BioAge Labs (NASDAQ: BIOA) CMO exercises options, sells 8,820 shares at $17.81

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

BioAge Labs, Inc. Chief Medical Officer Paul D. Rubin exercised stock options and then sold the resulting shares. On April 1, 2026, he exercised options covering 8,820 shares of common stock at strike prices of $4.11 and $6.57 per share.

The same day, he sold 8,820 shares of common stock at $17.81 per share in an open-market transaction, leaving 0 shares of common stock held directly after the sale. The filing notes that the transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 5, 2024.

Positive

  • None.

Negative

  • None.
Insider RUBIN PAUL D
Role Chief Medical Officer
Sold 8,820 shs ($157K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 5,437 $0.00 --
Exercise Stock Option (Right to Buy) 3,383 $0.00 --
Exercise Common Stock 5,437 $4.11 $22K
Exercise Common Stock 3,383 $6.57 $22K
Sale Common Stock 8,820 $17.81 $157K
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 5,437 shares (Direct)
Footnotes (1)
  1. The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024. This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Shares sold 8,820 shares Common stock sold on April 1, 2026
Sale price $17.81 per share Open-market sale of common stock
Options exercised (tranche 1) 5,437 shares at $4.11 Stock Option (Right to Buy), exercise or conversion
Options exercised (tranche 2) 3,383 shares at $6.57 Stock Option (Right to Buy), exercise or conversion
Total options exercised 8,820 shares ExerciseShares in transactionSummary
Shares held after sale 0 shares Total shares of common stock following transaction
10b5-1 plan adoption date November 5, 2024 Rule 10b5-1 trading plan footnote
Rule 10b5-1 trading plan regulatory
"The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy financial
""security_title": "Stock Option (Right to Buy)","
derivative exercise/conversion financial
""transaction_action": "derivative exercise/conversion","
open-market sale financial
""transaction_action": "open-market sale","
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Exercise or conversion of derivative security financial
""transaction_code_description": "Exercise or conversion of derivative security","
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
RUBIN PAUL D
(Last)(First)(Middle)
C/O BIOAGE LABS, INC.
5885 HOLLIS STREET, SUITE 370
(Street)
EMERYVILLE CALIFORNIA 94608
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BioAge Labs, Inc. [ BIOA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/01/2026M(1)5,437A$4.115,437D
Common Stock04/01/2026M(1)3,383A$6.578,820D
Common Stock04/01/2026S(1)8,820D$17.810D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$4.1104/01/2026M(1)5,437 (2)06/30/2030Common Stock5,437$00D
Stock Option (Right to Buy)$6.5704/01/2026M(1)3,383 (3)05/28/2032Common Stock3,383$00D
Explanation of Responses:
1. The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 5, 2024.
2. This option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on May 11, 2024.
3. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vested on April 1, 2022, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
/s/ Dov A. Goldstein as attorney-in-fact04/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did BIOA’s Chief Medical Officer report on this Form 4?

BioAge Labs’ Chief Medical Officer Paul D. Rubin reported exercising stock options for 8,820 common shares and then selling all 8,820 shares. The transactions occurred on April 1, 2026 and are detailed as option exercises followed by an open-market sale.

How many BioAge Labs (BIOA) shares did the CMO sell and at what price?

Paul D. Rubin sold 8,820 shares of BioAge Labs common stock at $17.81 per share. This sale followed the exercise of stock options into the same number of shares on April 1, 2026, according to the Form 4 filing.

What stock options did BIOA’s CMO exercise in this Form 4 filing?

He exercised two tranches of stock options: 5,437 options with a $4.11 exercise price and 3,383 options with a $6.57 exercise price. Together, these options converted into 8,820 shares of BioAge Labs common stock on April 1, 2026.

Was the BIOA insider sale by the CMO made under a Rule 10b5-1 plan?

Yes. The Form 4 states the transaction was executed under a Rule 10b5-1 trading plan adopted by Paul D. Rubin on November 5, 2024. Such plans pre-schedule trades, making the timing more routine and less discretionary.

What are the CMO’s direct BioAge Labs (BIOA) common stock holdings after this Form 4?

After the reported transactions, Paul D. Rubin directly holds 0 shares of BioAge Labs common stock. The Form 4 lists 8,820 shares sold and shows total shares of common stock following the sale as zero in his direct ownership.

How many derivative shares did BIOA’s CMO exercise in this Form 4?

The filing shows he exercised derivative securities representing 8,820 underlying common shares. This includes 5,437 and 3,383 stock options, which were fully converted into common stock before being sold in the same Form 4-reported sequence.